Tech Company Financing Transactions
Muse bio Funding Round
Muse bio closed a $23 million Series B funding round on 3/1/2017. Investors included Venrock, Foresite Capital and NanoDimension.
Transaction Overview
Company Name
Announced On
3/1/2017
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series B
Investors
Proceeds Purpose
The proceeds from this financing will allow us to accelerate our timelines to bring ForgeCraft to scientists worldwide.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4001 Discovery Dr. N321 UCB 027
Boulder, CO 80309
USA
Boulder, CO 80309
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Ness
Chief Scientific Officer
Ryan Gill
Chief Technical Officer
Tanya Lipscomb
VP - Bus. Development
Joey Money
VP - Finance
Erik Warneke
Browse more venture capital transactions:
Prev: 3/1/2017: Yoco venture capital transaction
Next: 3/1/2017: Belong venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs